tetano
Editor, Senior Moderator
Microbiol Spectr
. 2023 Jun 12;e0119023.
doi: 10.1128/spectrum.01190-23. Online ahead of print. A Novel Conserved Linear Neutralizing Epitope on the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein
Rong-Hong Hua[SUP] 1 [/SUP], Shu-Jian Zhang[SUP] 1 [/SUP], Bei Niu[SUP] 1 [/SUP], Jin-Ying Ge[SUP] 1 [/SUP], Ting Lan[SUP] 1 [/SUP], Zhi-Gao Bu[SUP] 1 [/SUP]
Affiliations
The continuous emergence of new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made it challenging to develop broad-spectrum prophylactic vaccines and therapeutic antibodies. Here, we have identified a broad-spectrum neutralizing antibody and its highly conserved epitope in the receptor-binding domain (RBD) of the spike protein (S) S1 subunit of SARS-CoV-2. First, nine monoclonal antibodies (MAbs) against the RBD or S1 were generated; of these, one RBD-specific MAb, 22.9-1, was selected for its broad RBD-binding abilities and neutralizing activities against SARS-CoV-2 variants. An epitope of 22.9-1 was fine-mapped with overlapping and truncated peptide fusion proteins. The core sequence of the epitope, [SUP]405[/SUP]D(N)EVR(S)QIAPGQ[SUP]414[/SUP], was identified on the internal surface of the up-state RBD. The epitope was conserved in nearly all variants of concern of SARS-CoV-2. MAb 22.9-1 and its novel epitope could be beneficial for research on broad-spectrum prophylactic vaccines and therapeutic antibody drugs. IMPORTANCE The continuous emergence of new variants of SARS-CoV-2 has caused great challenge in vaccine design and therapeutic antibody development. In this study, we selected a broad-spectrum neutralizing mouse monoclonal antibody which recognized a conserved linear B-cell epitope located on the internal surface of RBD. This MAb could neutralize all variants until now. The epitope was conserved in all variants. This work provides new insights in developing broad-spectrum prophylactic vaccines and therapeutic antibodies.
Keywords: SARS-CoV-2; epitope; neutralizing antibody; receptor-binding domain; spike protein.
. 2023 Jun 12;e0119023.
doi: 10.1128/spectrum.01190-23. Online ahead of print. A Novel Conserved Linear Neutralizing Epitope on the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein
Rong-Hong Hua[SUP] 1 [/SUP], Shu-Jian Zhang[SUP] 1 [/SUP], Bei Niu[SUP] 1 [/SUP], Jin-Ying Ge[SUP] 1 [/SUP], Ting Lan[SUP] 1 [/SUP], Zhi-Gao Bu[SUP] 1 [/SUP]
Affiliations
- PMID: 37306579
- DOI: 10.1128/spectrum.01190-23
The continuous emergence of new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made it challenging to develop broad-spectrum prophylactic vaccines and therapeutic antibodies. Here, we have identified a broad-spectrum neutralizing antibody and its highly conserved epitope in the receptor-binding domain (RBD) of the spike protein (S) S1 subunit of SARS-CoV-2. First, nine monoclonal antibodies (MAbs) against the RBD or S1 were generated; of these, one RBD-specific MAb, 22.9-1, was selected for its broad RBD-binding abilities and neutralizing activities against SARS-CoV-2 variants. An epitope of 22.9-1 was fine-mapped with overlapping and truncated peptide fusion proteins. The core sequence of the epitope, [SUP]405[/SUP]D(N)EVR(S)QIAPGQ[SUP]414[/SUP], was identified on the internal surface of the up-state RBD. The epitope was conserved in nearly all variants of concern of SARS-CoV-2. MAb 22.9-1 and its novel epitope could be beneficial for research on broad-spectrum prophylactic vaccines and therapeutic antibody drugs. IMPORTANCE The continuous emergence of new variants of SARS-CoV-2 has caused great challenge in vaccine design and therapeutic antibody development. In this study, we selected a broad-spectrum neutralizing mouse monoclonal antibody which recognized a conserved linear B-cell epitope located on the internal surface of RBD. This MAb could neutralize all variants until now. The epitope was conserved in all variants. This work provides new insights in developing broad-spectrum prophylactic vaccines and therapeutic antibodies.
Keywords: SARS-CoV-2; epitope; neutralizing antibody; receptor-binding domain; spike protein.